登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，3月20日，Treatment for severe acute respiratory distress syndrome from COVID-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-21

  • Treatment for severe acute respiratory distress syndrome from COVID-19

    Michael A Matthay

    J Matthew Aldrich

    Jeffrey E Gotts

    Published:March 20, 2020DOI:https://doi.org/10.1016/S2213-2600(20)30127-2

    In The Lancet Respiratory Medicine, Kollengode Ramanathan and colleagues1 provide excellent recommendations for the use of extracorporeal membrane oxygenation (ECMO) for patients with respiratory failure from acute respiratory distress syndrome (ARDS) secondary to coronavirus disease 2019 (COVID-19). The authors describe pragmatic approaches to the challenges of delivering ECMO to patients with COVID-19, including training health-care personnel, resolving equipment and facilities issues, implementing systems for infection control and personal protection, providing overall support for health-care staff, and mitigating ethical issues.

  • 原文来源：https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30127-2/fulltext
133浏览量
原文链接
相关报告

  • 《LANCET，5月7日，COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-09
    • Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Giulio Cavalli, MD Giacomo De Luca, MD Corrado Campochiaro, MD Emanuel Della-Torre, MD Marco Ripa, MD Diana Canetti, MD et al. Show all authors Published:May 07, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30127-2 Background Mortality of patients with coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), and systemic inflammation is high. In areas of pandemic outbreak, the number of patients can exceed maximum capacity of intensive care units (ICUs), and, thus, these individuals often receive non-invasive ventilation outside of the ICU. Effective treatments for this population are needed urgently. Anakinra is a recombinant interleukin-1 receptor antagonist that might be beneficial in this patient population.
    42浏览量
    原文链接

  • 《LANCET，3月17日，COVID-19 in pregnant women – Authors' reply》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-18
    • COVID-19 in pregnant women – Authors' reply David Baud Eric Giannoni Léo Pomar Xiaolong Qi Karin Nielsen-Saines Didier Musso et al. Show all authors Published:March 17, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30192-4 We are grateful for the concerns of Manuel Schmidt and colleagues about our previous guidelines1 for pregnant women with suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. At the time we developed the algorithm (February, 2020), there were no data regarding potential vertical transmission from infected mothers and outcomes in newborns. To date, there has been no evidence of vertical transmission of coronavirus disease 2019 (COVID-19) based on two small clinical series.2, 3 According to WHO, delayed umbilical cord clamping is highly unlikely to increase the risk of transmitting pathogens from the mother to the fetus even in the case of maternal infection.4 Because the vernix caseosa contains antimicrobial peptides, we recommend leaving it in place until 24 h after birth.5 New data examining neonates from infected mothers could be reassuring, but transmission after birth via contact with infectious respiratory secretions is still a concern, and physical separation of mother from child should be considered. Separation is a standard practice in pulmonary tuberculosis and is discussed in cases of maternal influenza infection.6 Therefore, separation of the mother and her newborn baby should be individually discussed by an interdisciplinary team, considering local facilities and risk factors for adverse neonatal outcomes, such as prematurity and fetal distress.
    54浏览量
    原文链接